Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase 1, first-in-human study of TYRP1-TCB (RO7293583), a novel TYRP1-targeting CD3 T-cell engager, in metastatic melanoma: active drug monitoring to assess the impact of immune response on drug exposure.
Spreafico A, Couselo EM, Irmisch A, Bessa J, Au-Yeung G, Bechter O, Svane IM, Sanmamed MF, Gambardella V, McKean M, Callahan M, Dummer R, Klein C, Umaña P, Justies N, Heil F, Fahrni L, Opolka-Hoffmann E, Waldhauer I, Bleul C, Staack RF, Karanikas V, Fowler S. Spreafico A, et al. Among authors: au yeung g. Front Oncol. 2024 Mar 21;14:1346502. doi: 10.3389/fonc.2024.1346502. eCollection 2024. Front Oncol. 2024. PMID: 38577337 Free PMC article.
Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses.
Kang EY, Cheasley D, LePage C, Wakefield MJ, da Cunha Torres M, Rowley S, Salazar C, Xing Z, Allan P, Bowtell DDL, Mes-Masson AM, Provencher DM, Rahimi K, Kelemen LE, Fasching PA, Doherty JA, Goodman MT, Goode EL, Deen S, Pharoah PDP, Brenton JD, Sieh W, Mateoiu C, Sundfeldt K, Cook LS, Le ND, Anglesio MS, Gilks CB, Huntsman DG, Kennedy CJ, Traficante N; Australian Ovarian Cancer Study; DeFazio A, Kaufmann S, Churchman M, Gourley C, Stephens AN, Meagher NS, Ramus SJ, Antill YC, Campbell I, Scott CL, Köbel M, Gorringe KL; GAMuT Collaborators. Kang EY, et al. Mod Pathol. 2021 Jan;34(1):194-206. doi: 10.1038/s41379-020-0618-9. Epub 2020 Jul 28. Mod Pathol. 2021. PMID: 32724153 Free PMC article.
Imaging for assessment of cancer treatment response to immune checkpoint inhibitors can be complementary in identifying hypophysitis.
Galligan A, Iravani A, Lasocki A, Wallace R, Weppler AM, Sachithanandan N, Chiang C, Colman PG, Wentworth J, Spain L, Au-Yeung G, Lee B, Kay TWH, Hicks RJ, Sandhu S, Krishnamurthy B. Galligan A, et al. Among authors: au yeung g. Front Endocrinol (Lausanne). 2023 Nov 29;14:1295865. doi: 10.3389/fendo.2023.1295865. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 38093958 Free PMC article.
CCNE1 Amplification as a Therapeutic Target.
Au-Yeung G, Mileshkin L, Bowtell DDL. Au-Yeung G, et al. J Clin Oncol. 2023 Mar 20;41(9):1770-1773. doi: 10.1200/JCO.22.02267. Epub 2023 Feb 2. J Clin Oncol. 2023. PMID: 36730890 No abstract available.
FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment.
Iravani A, Osman MM, Weppler AM, Wallace R, Galligan A, Lasocki A, Hunter MO, Akhurst T, Hofman MS, Lau PKH, Kee D, Au-Yeung G, Sandhu S, Hicks RJ. Iravani A, et al. Eur J Nucl Med Mol Imaging. 2020 Nov;47(12):2776-2786. doi: 10.1007/s00259-020-04815-w. Epub 2020 Apr 21. Eur J Nucl Med Mol Imaging. 2020. PMID: 32338306
Efficacy of immune checkpoint inhibitors for in-transit melanoma.
Nan Tie E, Lai-Kwon J, Rtshiladze MA, Na L, Bozzi J, Read T, Atkinson V, Au-Yeung G, Long GV, McArthur GA, Sandhu S, Saw R, Walpole E, Menzies A, Smithers M, Gyorki DE. Nan Tie E, et al. J Immunother Cancer. 2020 May;8(1):e000440. doi: 10.1136/jitc-2019-000440. J Immunother Cancer. 2020. PMID: 32376722 Free PMC article.
47 results